title: Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report.
abstract: Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD.
authors.affiliation: Cadres Respiratory Diseases Department of Beijing Shijitan Hospital, Beijing 100038;
authors.forename: Xinying
authors.initials: X
authors.lastname: Xue
authors.forename: Qingliang
authors.initials: Q
authors.lastname: Xue
authors.forename: Yuxia
authors.initials: Y
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Pan
authors.forename: Kaifei
authors.initials: K
authors.lastname: Wang
authors.forename: Lina
authors.initials: L
authors.lastname: Zhang
authors.forename: Na
authors.initials: N
authors.lastname: Wang
authors.forename: Bing
authors.initials: B
authors.lastname: Yang
authors.forename: Jianxin
authors.initials: J
authors.lastname: Wang
keywords: combination treatment; gefitinib; interstitial lung disease; non-small cell lung cancer; prednisolone